SGLT2 inhibitors show significant kidney protection for chronic kidney disease regardless of diabetes status or albumin levels.
Natalie Staplin, PhD
Advertisement
Natalie Staplin, PhD, a senior statistician within the Renal Studies Group at the Clinical Trials Service Unit & Epidemiological Studies Unit at the University of Oxford.
Articles by Natalie Staplin, PhD
An ERA 2025 analysis confirms empagliflozin significantly lowers acute kidney injury risk, reassuring clinicians about its safety in at-risk patients.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
SimpleScreen CRC Blood Test Meets Endpoints in Clinical Validation Study
2
Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B
3
Eplontersen Misses Primary Endpoint in Phase 3 ATTR-CM Trial
4
Biologic Therapy for Asthma and COPD: Real-World Perspectives From APPs
5